NASDAQ:PCRX

Pacira BioSciences (PCRX) Stock Forecast, Price & News

$33.15

-0.49 (-1.46%)

(As of 09/22/2023 ET)

Compare

Today's Range: $32.97
▼
$34.29
50-Day Range: $32.97
▼
$39.48
52-Week Range: $32.67
▼
$58.10

Volume: 260,059 shs
Average Volume: 550,140 shs
Market Capitalization: $1.54 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $58.00

Pacira BioSciences MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.89 Rating Score
Upside/Downside: 75.0% Upside
$58.00 Price Target
Short Interest: Bearish
7.69% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -1.97
Upright™ Environmental Score
News Sentiment: N/A
Insider Trading: Selling Shares
$42,773 Sold Last Quarter
Proj. Earnings Growth: 39.66%
From $2.37 to $3.31 Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.59 out of 5 stars

Medical Sector

71st out of 968 stocks

Pharmaceutical Preparations Industry

16th out of 445 stocks

4.4

Analyst's Opinion

Consensus Rating
Pacira BioSciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.89, and is based on 8 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $58.00, Pacira BioSciences has a forecasted upside of 75.0% from its current price of $33.15.
Amount of Analyst Coverage
Pacira BioSciences has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

2.0

Short Interest

Percentage of Shares Shorted
7.69% of the outstanding shares of Pacira BioSciences have been sold short.
Short Interest Ratio / Days to Cover
Pacira BioSciences has a short interest ratio ("days to cover") of 6.3.
Change versus previous month
Short interest in Pacira BioSciences has recently decreased by 4.80%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Pacira BioSciences does not currently pay a dividend.
Dividend Growth
Pacira BioSciences does not have a long track record of dividend growth.

3.7

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Pacira BioSciences has received a 48.44% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Bupivacaine", "Cryotherapy devices", and "Drug delivery devices" products. See details.
Environmental Sustainability
The Environmental Impact score for Pacira BioSciences is -1.97.

0.6

News and Social Media Coverage

MarketBeat Follows
1 people have added Pacira BioSciences to their MarketBeat watchlist in the last 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Pacira BioSciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $42,773.00 in company stock.
Percentage Held by Insiders
Only 6.60% of the stock of Pacira BioSciences is held by insiders.
Percentage Held by Institutions
99.73% of the stock of Pacira BioSciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.9

Earnings and Valuation

Earnings Growth
Earnings for Pacira BioSciences are expected to grow by 39.66% in the coming year, from $2.37 to $3.31 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Pacira BioSciences is -207.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Pacira BioSciences is -207.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Pacira BioSciences has a P/B Ratio of 1.96. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Pacira BioSciences (NASDAQ:PCRX) Stock

Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature only to targeted nerves. It also develops proprietary multivesicular liposome, a drug delivery technology that encapsulates drugs without altering their molecular structure. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.

PCRX Price History

30 days | 90 days | 365 days | Advanced Chart

PCRX Stock News Headlines

September 6, 2023 | finance.yahoo.com

Pacira BioSciences Announces Fireside Chat at the H.C. Wainwright 25th Annual Global Investment Conference

August 5, 2023 | seekingalpha.com

Pacira BioSciences: Economic Returns Languish Required Growth Rates

September 22, 2023 | Stansberry Research (Ad)

Are "The Magnificent Seven" the Next Sears?

The former retail giant’s sales once accounted for 1% of the U.S. economy. Now it’s nearly extinct. Will the same happen to big tech? Learn more here.

August 4, 2023 | msn.com

Needham Maintains Pacira BioSciences (PCRX) Buy Recommendation

August 4, 2023 | msn.com

TD Cowen Upgrades Pacira BioSciences (PCRX)

August 3, 2023 | markets.businessinsider.com

4 Analysts Have This to Say About Pacira BioSciences

August 3, 2023 | finance.yahoo.com

Pacira (PCRX) Q2 Earnings and Sales Miss, '23 View Updated

August 2, 2023 | finance.yahoo.com

Pacira BioSciences Reports Second Quarter 2023 Financial Results

September 22, 2023 | Stansberry Research (Ad)

Are "The Magnificent Seven" the Next Sears?

The former retail giant’s sales once accounted for 1% of the U.S. economy. Now it’s nearly extinct. Will the same happen to big tech? Learn more here.

August 2, 2023 | markets.businessinsider.com

Pacira Pharmaceuticals earnings preview: what Wall Street is expecting

July 27, 2023 | finance.yahoo.com

Pacira to Report Second Quarter 2023 Financial Results on Wednesday August 2, 2023

July 13, 2023 | benzinga.com

HC Wainwright & Co. Maintains Buy on Pacira BioSciences, Lowers Price Target to $68

July 13, 2023 | msn.com

HC Wainwright & Co. Maintains Pacira BioSciences (PCRX) Buy Recommendation

July 13, 2023 | markets.businessinsider.com

Analyst Ratings for Pacira BioSciences

July 5, 2023 | finance.yahoo.com

PCRX - Pacira BioSciences, Inc.

July 2, 2023 | fool.com

Pacira BioSciences (NASDAQ: PCRX)

June 26, 2023 | markets.businessinsider.com

Barclays Releases a Buy Rating on Pacira Pharmaceuticals (PCRX)

June 2, 2023 | finance.yahoo.com

Why Is Pacira (PCRX) Down 11.8% Since Last Earnings Report?

May 31, 2023 | finance.yahoo.com

Pacira BioSciences to Participate in Fireside Chat at the 2023 Jefferies Healthcare Conference

May 18, 2023 | seekingalpha.com

Pacira Biosciences (PCRX) Investor Presentation - Slideshow

May 15, 2023 | msn.com

Here's Why You Should Add Pacira (PCRX) Stock to Your Portfolio

May 10, 2023 | seekingalpha.com

Pacira BioSciences: Zilretta Story Still Viable, Productivity The Next Step

May 9, 2023 | msn.com

Looking Into Pacira BioSciences's Return On Capital Employed

May 9, 2023 | finance.yahoo.com

Pacira BioSciences to Participate in Fireside Chat at the 2023 RBC Capital Markets Global Healthcare Conference

May 4, 2023 | markets.businessinsider.com

Wedbush Reaffirms Their Buy Rating on Pacira Pharmaceuticals (PCRX)

May 4, 2023 | msn.com

RBC Capital Maintains Pacira BioSciences (PCRX) Outperform Recommendation

May 4, 2023 | msn.com

HC Wainwright & Co. Reiterates Pacira BioSciences (PCRX) Buy Recommendation

See More Headlines

Receive PCRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pacira BioSciences and its competitors with MarketBeat's FREE daily newsletter.

PCRX Company Calendar

Last Earnings: 8/02/2023
Today: 9/22/2023
Next Earnings (Estimated): 11/02/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: Pharmaceuticals
Sector: Medical
Current Symbol: NASDAQ:PCRX
CUSIP: 69512710
CIK: 1396814
Web: www.pacira.com
Phone: (813) 553-6680
Fax: 302-655-5049
Employees: 715
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $58.00
High Stock Price Forecast: $80.00
Low Stock Price Forecast: $50.00
Forecasted Upside/Downside: +75.0%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.89
Research Coverage: 9 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.16)
Trailing P/E Ratio: N/A
Forward P/E Ratio: 13.99
P/E Growth: N/A
Net Income: $15.91 million
Net Margins: -0.68%
Pretax Margin: -0.69%
Return on Equity: 11.56%
Return on Assets: 5.57%

Debt

Debt-to-Equity Ratio: 0.66
Current Ratio: 3.94
Quick Ratio: 3.10

Sales & Book Value

Annual Sales: $666.82 million
Price / Sales: 2.31
Cash Flow: $3.86 per share
Price / Cash Flow: 8.58
Book Value: $16.89 per share
Price / Book: 1.96

Miscellaneous

Outstanding Shares: 46,420,000
Free Float: 43,353,000
Market Cap: $1.54 billion
Optionable: Optionable
Beta: 0.70

The Best High-Yield Dividend Stocks for 2023

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

Mr. David M. Stack (Age 73)
Chairman & CEO
Comp: $1.54M

Mr. Charles A. Reinhart III (Age 62)
CPA, M.B.A., Chief Financial Officer
Comp: $780.58k

Mr. Daryl Gaugler (Age 61)
Chief Operating Officer
Comp: $778.77k

Ms. Kristen Williams J.D. (Age 49)
Chief Admin. Officer & Sec.
Comp: $799.63k

Mr. Anthony Molloy III (Age 49)
Esq., Chief Legal & Compliance Officer
Comp: $581.41k

Ms. Lauren Bullaro Riker (Age 44)
Principal Accounting Officer & VP of Fin.

Susan Mesco
Head of Investor Relations

Mr. Richard Kahr
VP of HR

Dr. Roy Winston M.D. (Age 62)
Chief Medical Officer & Orthopedic Franchise

Mr. Dennis McLoughlin (Age 57)
Chief Customer Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

PCRX Stock - Frequently Asked Questions

Should I buy or sell Pacira BioSciences stock right now?: 9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Pacira BioSciences in the last twelve months. There are currently 1 hold rating and 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" PCRX shares.
View PCRX analyst ratings or view top-rated stocks.
What is Pacira BioSciences' stock price forecast for 2023?: 9 Wall Street analysts have issued twelve-month target prices for Pacira BioSciences' shares. Their PCRX share price forecasts range from $50.00 to $80.00. On average, they expect the company's share price to reach $58.00 in the next year. This suggests a possible upside of 75.0% from the stock's current price.
View analysts price targets for PCRX or view top-rated stocks among Wall Street analysts.
How have PCRX shares performed in 2023?: Pacira BioSciences' stock was trading at $38.61 on January 1st, 2023. Since then, PCRX shares have decreased by 14.1% and is now trading at $33.15.
View the best growth stocks for 2023 here.
When is Pacira BioSciences' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our PCRX earnings forecast.
How were Pacira BioSciences' earnings last quarter?: Pacira BioSciences, Inc. (NASDAQ:PCRX) announced its quarterly earnings data on Wednesday, August, 2nd. The company reported $0.61 EPS for the quarter, topping analysts' consensus estimates of $0.59 by $0.02. The firm had revenue of $169.47 million for the quarter, compared to the consensus estimate of $175.64 million. Pacira BioSciences had a negative net margin of 0.68% and a positive trailing twelve-month return on equity of 11.56%.
What ETFs hold Pacira BioSciences' stock?: ETFs with the largest weight of Pacira BioSciences (NASDAQ:PCRX) stock in their portfolio include Invesco Pharmaceuticals ETF (PJP), SPDR S&P Pharmaceuticals ETF (XPH), Invesco S&P SmallCap Health Care ETF (PSCH) and Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL).iShares U.S. Pharmaceuticals ETF (IHE).
What is Dave Stack's approval rating as Pacira BioSciences' CEO?: 54 employees have rated Pacira BioSciences Chief Executive Officer Dave Stack on Glassdoor.com. Dave Stack has an approval rating of 45% among the company's employees. This puts Dave Stack in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Pacira BioSciences own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Pacira BioSciences investors own include Gilead Sciences (GILD), NVIDIA (NVDA), Micron Technology (MU), ACADIA Pharmaceuticals (ACAD), Skyworks Solutions (SWKS), AbbVie (ABBV), Pfizer (PFE), QUALCOMM (QCOM), Exelixis (EXEL) and Tesla (TSLA).
What is Pacira BioSciences' stock symbol?: Pacira BioSciences trades on the NASDAQ under the ticker symbol "PCRX."
Who are Pacira BioSciences' major shareholders?: Pacira BioSciences' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Frontier Capital Management Co. LLC (3.63%), Baillie Gifford & Co. (3.61%), Renaissance Technologies LLC (3.39%), Stephens Investment Management Group LLC (2.88%), Clearbridge Investments LLC (2.49%) and Dimensional Fund Advisors LP (2.42%). Insiders that own company stock include Andreas Wicki, Anthony Molloy, Charles A Reinhart III, Charles Anthony Laranjeira, Daryl Gaugler, David M Stack, David M Stack, Donald C Manning, Gary W Pace, John P Phd Longenecker, Jonathan Slonin, Kristen Marie Williams, Laura Brege, Lauren Bullaro Riker, Mark A Kronenfeld, Mark Froimson, Max Reinhardt, Paul J Hastings and Roy Winston.
View institutional ownership trends.
How do I buy shares of Pacira BioSciences?: Shares of PCRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Pacira BioSciences' stock price today?: One share of PCRX stock can currently be purchased for approximately $33.15.
How much money does Pacira BioSciences make?: Pacira BioSciences (NASDAQ:PCRX) has a market capitalization of $1.54 billion and generates $666.82 million in revenue each year. The company earns $15.91 million in net income (profit) each year or ($0.16) on an earnings per share basis.
How many employees does Pacira BioSciences have?: The company employs 715 workers across the globe.
How can I contact Pacira BioSciences?: Pacira BioSciences' mailing address is 5 SYLVAN WAY SUITE 300, PARSIPPANY NJ, 07054. The official website for the company is www.pacira.com. The company can be reached via phone at (813) 553-6680, via email at susan.mesco@pacira.com, or via fax at 302-655-5049.

This page (NASDAQ:PCRX) was last updated on 9/22/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial